The FDA decision is primarily informed by the positive results of a proof-of-concept, Phase 2a study evaluating the safety, immunogenicity, and efficacy of a single dose of 120µg RSVpreF in a human viral challenge model in healthy adults 18 to 50 years of age
Organizations to combine expertise to further develop AI/ML-powered drug design platform, delivering precise, effective, and life-changing medicines at scale
Data to establish the safety profile and human dose of vaccine candidate
The study was published recently in Genome Medicine, a leading international journal focused on translational, genomic-based medicine
Prof. Kypros has revolutionised the field of fetal medicine through his extensive research and medical practice achievements, including introducing intrauterine blood transfusions for fetal anaemia
Building the future of food in the birthplace of cell-cultured milk
New data, including two late-breaking clinical trial presentations on mavacamten and a new analysis of the GUARD-AF study, reinforce the company’s continued commitment to those living with cardiovascular disease
The approval is based on new data from cohorts D and K of the KEYNOTE-158 trial
Milltrust Ventures will also assist Oncoshot with its expansion in Australia and India, where the latter has already established partnerships amongst apex cancer institutes
She joined Trivitron Healthcare in 1999 and has held several positions in the organisation
Subscribe To Our Newsletter & Stay Updated
